Lacosamide Stragen (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilising neuronal membranes and limiting repetitive firing. This selective action diminishes neuronal hyper‑excitability that underlies seizure generation.

The dosing regimen for Lacosamide Stragen is determined by the prescribing clinician based on the patient’s clinical condition, age, renal function and concomitant therapies. The prescriber sets the appropriate infusion rate and total daily dose.

The pregnancy safety category for Lacosamide is unknown. It should only be used during pregnancy when the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding; caution is advised and a risk‑benefit assessment should be performed.

To request Lacosamide Stragen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional agents that block fast sodium channels. This can offer additive seizure control when combined with other anti‑epileptics, and it may have a more favourable cognitive profile compared with some older drugs.

Lacosamide Stragen should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability.

Lacosamide Stragen is given by intravenous infusion. The infusion rate and total daily dose are set by the treating physician, typically administered over a period of 15‑30 minutes, with monitoring for cardiac and neurological effects.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, atrial fibrillation, and rare severe skin reactions. Patients should be monitored for signs of arrhythmia, hypersensitivity, and any emergent psychiatric symptoms.

Lacosamide Stragen is contraindicated in patients with known hypersensitivity to lacosamide or any excipients in the formulation. Caution is also advised for individuals with significant cardiac conduction disorders, severe renal impairment, or those taking interacting medications that cannot be safely managed.